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Abstract
Background: Obesity is associated with functional impairment, institutionalization, and increased mortality risk in
elders. Dynapenia is defined as reduced muscle strength and is a known independent predictor of adverse events
and disability. The synergy between dynapenia and obesity leads to worse outcomes than either independently.
We identified the impact of dynapenic obesity in a cohort at risk for and with knee osteoarthritis on function.
Methods: We identified adults aged ≥ 60 years from the Osteoarthritis Initiative. Obesity was defined as a body
mass index ≥ 30 kg/m2. Dynapenia was classified using the lowest sex-specific tertile of knee extensor strength.
Participants were grouped according to obesity and knee strength: dynapenic obesity; dynapenia without obesity;
obesity without dynapenia; and no dynapenia nor obesity. Four-year data was available. Self-reported activities of
daily living (ADL) were assessed at follow-up. Outcomes of gait speed, 400 m walk distance, Late-life Disability and
Function Index (LLFDI), and Short-Form (SF)-12 were analyzed using mixed effects and logistic regression models.
Results: Of 2025 subjects (56.3 % female), mean age was 68.2 years and 182 (24.1 %) had dynapenic obesity.
Dynapenic obesity was associated with reduced gait speed, LLFDI-limitations, and SF-12 physical score in both
sexes and in the 400 m walk in men only (all p < 0.001). A time*group interaction was significant for dynapenic
obese men in the 400 m walk distance only. Odds of ADL limitations in dynapenic obesity was OR 2.23 [1.42:3.50],
in dynapenia 0.98 [0.66:1.46], and in obesity 1.98 [1.39:2.80] in males. In females, odds were 2.45 [1.63:3.68], 1.60
[1.15:2.22], and 1.47 [1.06:2.04] respectively.
Conclusion: Dynapenic obesity may be a risk factor for functional decline suggesting the need to target subjects
with low knee strength and obesity.
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Background
The obesity epidemic is observed even in an aging popu-
lation with an overall prevalence in older United States
adults of 35.4 % [1]. Both obesity and aging independ-
ently lead to adverse outcomes for older adults, includ-
ing risk of long-term disability [2], institutionalization
[3] and impaired quality of life [4]. Dynapenia, reflected
by muscle weakness or low muscle strength, is a compo-
nent of sarcopenia [5], a condition characterized by the
loss of muscle mass during the aging process. Sarcopenia
is associated with detrimental outcomes independent of
aging and obesity [2]. Recent evidence suggests that
mechanistic similarities underlie sarcopenia and obesity
in aging [6]. The combination of these conditions in
those surviving into old age creates additional challenges
during the aging process, therefore, identifying people at
high risk is extremely important in order to target spe-
cific interventions.
The synergy of sarcopenia and obesity leads to a high
risk of adverse outcomes in affected individuals [7].
Challenges exist in adequately defining the relationship
between sarcopenia and obesity which has impeded pro-
gress in characterizing the syndrome [5]. A number of
studies have looked at the relationship between muscle
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mass, obesity and their long-term outcomes [2, 8, 9]. In
contrast, dynapenia alone may also lead to adverse, unin-
tended outcomes [10–13]. Previous studies have focused
uniquely on cross-sectional relationships demonstrating
the relationship of obesity and low muscle strength with
impaired function [14, 15]. Emerging evidence has proven
that dynapenic obesity (measured by waist circumference)
may also be related to a higher risk of functional decline
[14, 16] and death [17].
To our knowledge, there is very little data demonstrat-
ing the higher, yet theoretical, cumulative risk of dynape-
nia with obesity than with either disorder on its own.
Understanding the natural history of patients with dyna-
penia and obesity is critically needed to allow clinicians
to intervene in this at-risk population. Additionally, lon-
gitudinal data will allow a description of the time course
of the observed decline, in particular, in a dataset that
has a well characterized sample that includes both pre-
dictors and outcomes of interest. The purpose of this
study was to characterize the effect of dynapenic obesity
on physical functioning in a cohort at risk, and with
osteoarthritis. We hypothesized that this subgroup is at
risk for a faster decline in function and quality of life
over time.
Methods
We performed a secondary analysis of data using The
Osteoarthritis Initiative (OAI), a multi-center, longitu-
dinal, prospective observational study of people with knee
osteoarthritis that begun in 2004. The study was funded
through a public-private partnership whose goal was to
evaluate the natural course and biomarkers of the onset
and progression of knee osteoarthritis. There were four re-
cruitment sites including Baltimore, MD, Columbus, OH,
Pawtuckett, RI, and Pittsburgh, PA. Recruitment and en-
rollment procedures, which have been described else-
where, were carried out within a 6-week time frame.
Informed consent followed all pertinent federal guidelines
with each component explained to potential participants,
prior to screening or enrollment. Written consent was ob-
tained prior to each clinic visit following thorough de-
scription of the study and its components by a trained
staff member, answering questions, with a copy provided
for review to participants before the scheduled visit. Docu-
mentation describing various aspects of the design and
methods of the OAI is publically available on the OAI On-
line website (http://www.oai.ucsf.edu/). For this particular
study, data at baseline, 1, 2, and 4 years were included.
The local ethics committee (Institutional Review Board) at
Dartmouth, the Committee for the Protection of Human
Subjects, in Hanover, New Hampshire, exempted this
present study from ethical approval due to the de-
identified nature of the data. The OAI had a separate
process approving the study, with each clinical center
modifying the consent form template to comply with local
Institutional requirements.
Study cohort
An ethnically diverse sample of men and women (age
range 45–79 years) was interviewed for eligibility, and
then assigned to a sub-cohort: subjects with clinically
significant radiographic tibiofemoral knee OA in at least
one native knee (progression cohort); subjects without
symptomatic knee OA in either knee at baseline but
consisting of established OA risk factors including
Heberden nodes, previous knee operation or injury, fam-
ily history, pain in the knee in the preceding month and
weight defined using gender and age-specific cut-points
(incidence cohort); and subjects without any pain or
radiographic findings or risk factors (control cohort).
OAI exclusion criteria consisted of individuals with
rheumatoid arthritis, severe joint space narrowing, bilat-
eral total knee arthroplasty, inability to undergo an MRI
or able to provide a blood sample, co-morbidity interfer-
ing with study participation, individuals subject to moving
from the study catchment area within 3 years, or other re-
search participation. For this study, subjects <60 years of
age were excluded (n = 2221) due to a lower risk of func-
tional impairment [18] and higher capacity for homeosta-
sis [19]. There were 560 subjects who died, had incident
knee arthroplasty or had missing knee extensor strength
values, and were therefore excluded as well. Participant
flow is depicted in Fig. 1.
Covariates
Standardized questionnaires, interviews, and assess-
ments provided the basis for all self-reported variables
and measurements. The age of the individual at the ini-
tial visit was considered baseline age. Education status
was classified in four categories: attended high school
with or without graduation, attended college, college
graduate, or post-graduate education. Marital status was
defined as single or married, where the former included
subjects who lost a spouse, divorced, separated or never
married. Ever smokers were defined as a person who
smoked greater than 100 cigarettes in their lifetime. The
Western Ontario and McMaster University OA Index
(WOMAC) [20] assessed self-reported knee pain
using a 5-point Likert scale about knee pain in each
limb separately over the past 7 days, with scores ran-
ging from 0 to 20. Higher scores represent worse
symptoms. The Charlson co-morbidity index assessed
subject co-morbidity [21]. All deaths were subject to a for-
mal adjudication process through the OAI Coordinating
Center.
Physical activity was defined using the Physical Activity
Scale for the Elderly (PASE) scale [22], a 26-item instru-
ment measuring occupational, household, and leisure
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activities during a 1-week period in older adults. This self-
reported scale is reliable and valid, and can be adminis-
tered by telephone, mail or in-person. Higher scores are
associated with increased levels of activity and population-
based means are available [22, 23]. Importantly, no min-
imally clinically important differences are available.
Definition of dynapenic obesity
Weight was measured in kilograms using a calibrated
standard balance beam scale. Subjects were asked to re-
move their shoes and heavy jewelry and wear light cloth-
ing. A wall-mounted stadiometer was used to measure
standing height. Body mass index (BMI) was calculated
as weight (in kilograms) divided by height (in meters)
squared. Obesity was classified according to standard
BMI categories: normal (18.5–24.9 kg/m2), overweight
(25–29.9 kg/m2), and obese (≥30 kg/m2). Waist circum-
ference (WC) was measured at the level of the umbilicus
between the lower rib and the iliac crest. A high WC
was classified as ≥88 cm or ≥102 cm in females and
males, respectively [24]. Using a good strength chair
with a supported back, knee extension was measured
with the knee joint at a 60° angle measured by a goni-
ometer. The transducer was centered behind the leg,
with the bottom 2 cm above the calcaneous, placed be-
hind the participant’s leg. After the leg was strapped,
three trials at maximal effort were performed, measured
in newtons (N). Full details are available online. Two prac-
tice trials were performed at 50 % effort, after a 15–20
min warm-up session. The greater of the left or right knee
extensor strength was used for maximal knee strength.
We classified dynapenia (yes/no) in each sex as partici-
pants in the lowest tertile of knee extensor strength
(males: 365.8, 458.2 N; females 235.3; 304.1 N). Four cat-
egories were created based on these combinations.
Self-reported outcomes
Perceived self-reported health was assessed using the
SF-12, a shorter questionnaire accounting for >90 % of
the statistical variance of the longer SF-36 [25]. A Likert
scale assessed both physical (PCS) and mental (MCS)
component scores. The score are standardized and
weighted to a population mean of 50 ± 10. Higher scores
represent better health.
Late-life Function and Disability Index (LLFDI) [26] is
a self-reported instrument with two main domains, dis-
ability and function, each scored on a 0–100 scale, with
higher scores indicating higher levels. The OAI mea-
sured the disability component, which is subdivided into
the frequency subscale that describes an individual’s regu-
larity of participation in life tasks, and a limitation scale that
describes the capability to perform life tasks. Personal fac-
tors such as health, physical or mental energy, and environ-
mental factors including transportation, accessibility and
Fig. 1 Participant Flow among 17,457 screened in the Osteoarthritis
Initiative Protocol. Patient flow is demonstrated from initial telephone
screen to cohort included in this study. Abbreviations: BMI—body
mass index; MRI—magnetic resonance imaging; OA—osteoarthritis;
WC—waist circumference
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socio-economic conditions were probed. The instrument
parallels the disablement framework described by Nagi on
disability in community-dwelling older adults and corre-
lates well with the physical functioning subscale of the
Medical Outcomes Study 36-item Short Form (SF) Health
Survey and the London Handicap Scale [27].
Activities of daily living (ADL) impairment was self-
reported. Subjects were classified as having impairment
in function if they were unable to perform a basic ADL
including, walking, bathing, dressing, eating, transferring
out of bed, or toileting [28].
Objectively measured outcomes
Gait speed, a measure of functional performance that
predicts impaired function and mortality [29], was
assessed using the 20 m walk test at a usual walking
pace. Subjects walked 20 m in an unobstructed dedi-
cated corridor, turned around and walked in the oppos-
ite direction. This measure has excellent reliability and
intra-class correlation. A minimally clinically significant
difference of 0.1 m/s is considered clinically significant
[30]. The 400 m walk test is a measure of aerobic cap-
acity related to V02 max that assesses physical fitness
[31]. Approximately 98.1 % of participants that could
complete the 20 m walk test were administered this
measure. Heart rate and blood pressure were assessed,
and questions related to recent cardiovascular history
were posed to screen individuals. A similar course to
that of the 20 m walk test was performed. Standard en-
couragement was given following every lap. As there
were subjects who were unable to complete this test, the
total distance traveled was used in lieu of the time to
complete the test.
Statistical analysis
All data was downloaded and merged into a single data-
base in October 2014 for analysis. All continuous vari-
ables are represented as means ± standard deviations,
and counts (percent). A one-way ANOVA assessed dif-
ferences amongst baseline characteristics within each
sex. Because functional measures and muscle strength
are affected by sex, we elected to perform sex-specific
analyses of all outcomes. A paired t-test assessed differ-
ences between baseline and follow-up at 4-years within
each category (dynapenic obesity; dynapenia without
obesity; obesity without dynapenia; Neither dynapenia
nor obesity). An ANOVA was also used to compare
mean scores between categories within a given time
frame (either baseline or follow-up at 4-years). Within-
person differences between baseline and follow-up were
compared across the four categories to assess changes.
Multiple comparison analyses were performed on all con-
tinuous variables in the unadjusted analyses (Bonferroni)
with results comparing the dynapenic obesity group with
all other subgroups (df = 3).
The primary outcome of interest was the association of
the four categories of dynapenia and obesity over time
with gait speed, 400 m walk, LLFDI and SF-12 subscales.
Linear mixed models tested these associations on all four
categories and time-main effects in addition to a time x
dynapenia/obesity-group interaction. This method tested
the differences between baseline and follow-up with
changes over time. All models were adjusted for age, edu-
cation, race, smoking status, PASE score, Charlson score,
and cohort type (incidence, progression and control). We
determined the impact of each dynapenia/obesity category
on risk of incident mobility limitations by sex and by age
group using logistic regression models. Odds ratios and
95 % confidence intervals were calculated. We classified
those without dynapenia or obesity as the referent cat-
egory. As an exploratory analysis, we stratified our analysis
by age group (60–70years and 70+ years) to examine the
impact of age. A sensitivity analysis compared subjects
included vs. excluded. All data was analyzed using
STATA version 12 (STATACorp, College Station, TX).
A p-value <0.05 was considered statistically significant.
Results
Baseline characteristics are presented in Table 1. Across
all four categories, there were differences in age, socio-
demographic factors, knee strength, BMI, and WOMAC
scores. There were differences in females only in Charlson
co-morbidity scores, smoking status, ADL impairments
and cohort allocation. As compared to dynapenia alone,
dynapenic obese patients had higher WOMAC scores
with similar post-hoc comparisons in other baseline vari-
ables in both sexes. Additional file 1 outlines the differ-
ences between subjects included and excluded. Those
excluded were older, had lower socioeconomic status, gait
speed and SF-12 scores, and had gait speed and SF-12
scores, and had higher comorbid conditions and
WOMAC scores. Table 2 displays the mean values at
baseline and 48-month follow-up of our unadjusted pri-
mary outcome stratified by sex. Similar trends across cat-
egories were observed in both sexes. Significant changes
were observed across groups in the 400 m walk (p < 0.001
and p = 0.03 in males and females, respectively), and dif-
ferences in LLFDI-frequency and limitation subdomains.
Dynapenic obese patients had a lower gait speed and SF-
12 PCS score compared to those with dynapenia alone in
both sexes at baseline. In males, baseline gait speed,
follow-up 400 m walk test and SF-12 PCS score were sig-
nificantly different in dynapenic obese subjects compared
to those with dynapenia alone. In females, follow-up gait
speed and SF-12 PCS scores were significantly different
between dynapenic obese subjects compared to dynapenia
alone. There were significantly higher unadjusted baseline
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Table 1 Baseline characteristics of the included cohort


















N = 2025 N = 68 N = 184 N = 186 N = 318 N = 114 N = 309 N = 296 N = 550
Age, years 68.2 ± 5.4 69.4 ± 5.5 70.5 ± 4.9 67.4 ± 5.1* 68.7 ± 5.4 <0.001 67.5 ± 5.7 69.1 ± 5.7* 66.3 ± 4.9 67.8 ± 5.1 <0.001
Education status
< High School 384 (18.9) 17 (25.0) 27 (14.8) 24 (13.0) 30 (9.4) 29 (25.4) 67 (21.7) 75 (25.5) 115 (21.0)
Some College 483 (23.9) 11 (16.2) 23 (12.6) 41 (22.2) 44 (13.8) 0.001 41 (36.0) 74 (24.0) 100 (24.0) 149 (27.2) 0.01
College 395 (19.5) 19 (27.9) 37 (20.2) 44 (23.8) 79 (24.8) 16 (14.0) 63 (20.4) 46 (15.7) 91 (16.6)
> College 756 (37.3) 21 (30.9) 96 (52.5) 76 (41.1) 165 (51.9) 28 (24.6) 105 (34.0) 73 (24.8) 192 (35.1)
Yearly income
> $50,000 1046 (51.7) 27 (43.6) 105 (59.0) 123 (68.0) 229 (74.4) <0.001 36 (33.0) 146 (50.0) 111 (39.9) 269 (52.1) <0.001
Marital status
Married 1340 (66.2) 49 (72.1) 141 (77.1) 149 (80.5) 274 (86.2) 0.01 54 (47.4) 184 (59.6) 146 (49.8) 343 (62.7) <0.001
Race
White 1710 (84.4) 51 (75.0) 158 (85.9) 159 (85.5) 297 (93.4) 69 (60.5) 263 (85.1) 215 (72.6) 498 (90.6)
Black 268 (13.2) 16 (23.5) 19 (10.3) 24 (12.9) 15 (4.7) <0.001 43 (37.7) 40 (12.9) 72 (24.3) 39 (7.1) <0.001
Other 47 (2.3 1 (1.5) 5 (2.7) 3 (1.6) 3 (0.9) 2 (1.8) 3 (1.0) 8 (2.7) 6 (1.1)
Charlson score 0.43 ± 0.88 0.66 ± 1.22 0.60 ± 1.07 0.67 ± 1.12 0.45 ± 0.93 0.11 0.57 ± 0.93 0.31 ± 0.72* 0.53 ± 0.93 0.26 ± 0.60# <0.001
PASE score 138.1 ± 67.3 123.5 ± 62.5 137.0 ± 68.9 150.3 ± 77.0* 160.3 ± 70.6# <0.001 106.8 ± 64.0 122.9 ± 55.3 130.7 ± 63.9* 142.5 ± 65.4# <0.001
Baseline WOMAC right 11.0 ± 13.6 14.1 ± 13.3 9.4 ± 10.2* 10.7 ± 13.4 6.9 ± 9.9# <0.001 23.8 ± 21.1 13.2 ± 14.3# 14.4 ± 15.3# 7.9 ± 10.6# <0.001
Baseline WOMAC left 10.6 ± 14.4 14.0 ± 15.0 8.8 ± 12.5* 11.3 ± 15.1 7.1 ± 11.2 <0.001 21.1 ± 20.2 11.4 ± 13.8# 14.1 ± 16.8# 8.1 ± 12.0# <0.001
Ever smoker 999 (39.3) 40 (59.7) 105 (58.0) 97 (53.0) 168 (52.8) 0.54 41 (36.6) 126 (41.2) 153 (52.4) 269 (49.5) 0.003
No. medications 3.80 ± 2.46 5.0 ± 2.7 3.87 ± 2.51* 4.05 ± 2.74* 3.17 ± 2.08# <0.001 4.47 ± 2.63 3.75 ± 2.62 4.21 ± 2.43 3.49 ± 2.23 <0.001
Body mass index, kg/m2 28.2 ± 4.5 33.1 ± 2.6 26.2 ± 2.3# 33.1 ± 2.8 26.6 ± 2.2# <0.001 33.6 ± 3.2 24.9 ± 2.9# 33.5 ± 2.9 25.5 ± 2.8# <0.001
Waist circumference, cm 103.1 ± 12.2 115.5 ± 8.8 99.3 ± 7.6# 115.3 ± 8.4 99.6 ± 7.3# <0.001 113.5 ± 10.7 96.1 ± 10.1# 113.8 ± 10.1 96.9 ± 9.8# <0.001
High waist circumference 1538 (76.0) 63 (95.5) 72 (39.3) 179 (96.8) 114 (36.4) <0.001 114 (100.0) 243 (78.9) 295 (100.0) 458 (83.6) <0.001












Table 1 Baseline characteristics of the included cohort (Continued)
Cohort allocation
Incidence 1492 (73.7) 43 (63.2) 142 (77.2) 124 (66.7) 242 (76.1) 56 (49.1) 236 (76.4) 197 (66.6) 450 (81.8)
Progression 526 (26.0) 25 (36.8) 41 (22.3) 61 (32.8) 73 (23.0) 0.06 58 (50.9) 72 (23.3) 99 (33.5) 99 (18.0) <0.001
Control 7 (0.4) — 1 (0.5) 1 (0.5) 3 (0.9) — 1 (0.2) — 1 (0.2)
ADL impairment 109 (7.2) 8 (16.7) 10 (20.8) 15 (31.3) 15 (31.3) 0.06 11 (18.0) 15 (24.6) 17 (27.9) 18 (29.5) 0.003
All values are represented as mean ± standard deviation, or count (%)
P-value represents the ANOVA across all body mass index categories
p-values represent analysis of variance between 4 quartile categories in each sex
Obesity represented as BMI ≥ 30 kg/m2; Dynapenia represented as lowest tertile in Males (Knee extensor strength < 365.8 N, and in Females (<235.3 N)
High waist circumference is ≥88 cm in females; ≥102 cm in males
Multiple comparison analyses performed between Dynapenic Obesity group and other groups: *P < 0.05; #P < 0.001












Table 2 Sex-specific unadjusted functional outcomes by dynapenia/obesity category—baseline and 48-month follow-up


















N = 68 N = 184 N = 186 N = 318 N = 114 N = 309 N = 296 N = 550
Gait Speed Baseline 1.21 ± 0.15 1.30 ± 0.21# 1.28 ± 0.19* 1.39 ± 0.18* <0.001 1.11 ± 0.23 1.27 ± 0.23# 1.22 ± 0.19# 1.33 ± 0.19# <0.001
Follow-up 1.19 ± 0.19 1.25 ± 0.20 1.26 ± 0.18 1.36 ± 0.19# <0.001 1.08 ± 0.22 1.23 ± 0.22# 1.19 ± 0.19# 1.31 ± 0.18# <0.001
p-valuea 0.05 0.009 0.05 <0.001 0.60c 0.03 <0.001 <0.001 <0.001 0.32c
400 M Walk Baseline 399.4 ± 4.9 399.3 ± 8.9 398.6 ± 19.3 398.7 ± 17.1 0.95 388.0 ± 54.5 397.8 ± 24.4* 394.1 ± 38.7# 397.7 ± 22.5* 0.01
Follow-up 366.1 ± 87.6 395.6 ± 30.4# 395.4 ± 29.4# 398.8 ± 18.0# <0.001 383.6 395.7 ± 35.4 387.0 ± 51.0 394.0 ± 36.6 0.05
p-valuea 0.01 0.20 0.07 0.59 <0.001c 0.04 0.08 <0.001 0.003 0.03c
LLDFI-Frequency Follow-up 52.6 ± 6.9 53.5 ± 6.3 53.9 ± 6.4 53.9 ± 5.1 0.004 54.5 ± 7.8 56.5 ± 6.3 55.1 ± 5.8 57.3 ± 6.5* <0.001
LLDFI Limitations Follow-up 75.3 ± 15.2 80.6 ± 15.2 82.4 ± 14.7* 85.2 ± 14.9# <0.001 75.2 ± 17.3 79.5 ± 14.2 78.5 ± 15.3 82.9 ± 14.5# <0.001
SF-12 PCS Baseline 43.8 ± 9.6 49.7 ± 7.6# 48.6 ± 7.9# 51.5 ± 7.0# <0.001 42.0 ± 10.9 48.2 ± 9.0# 47.6 ± 9.0# 50.8 ± 7.9# <0.001
Follow-up 41.0 ± 11.2 47.1 ± 8.5# 46.8 ± 8.7 #49.9 ± 8.0# <0.001 40.7 ± 11.5 47.1 ± 9.0* 45.3 ± 10.0# 49.5 ± 8.3# <0.001
p-valuea 0.003 <0.001 <0.001 <0.001 0.38c 0.09 0.001 <0.001 <0.001 0.20c
SF-12 MCS Baseline 55.1 ± 9.6 55.2 ± 7.6 55.2 ± 7.9 56.2 ± 7.0 0.006 53.3 ± 10.9 54.7 ± 9.0 53.7 ± 9.0 54.6 ± 7.9 0.17
Follow-up 55.4 ± 7.2 55.3 ± 8.0 54.5 ± 8.5 55.5 ± 6.9 0.59 54.6 ± 10.3 54.1 ± 8.1 53.5 ± 9.4 54.3 ± 7.6 0.59
p-valuea 0.52 0.89 0.25 0.13 0.50c 0.52 0.06 0.82 0.14 0.42c
Physical and Mental Component Scores are part of the Short-Form 12 assessment
Obesity represented as BMI ≥ 30 kg/m2; Dynapenia represented as lowest tertile in Males (Knee extensor strength <365.8 N, and in Females (<235.3 N)
A decrease in Gait Speed and 400 m walk test, represent reductions in mobility speed and fitness. Higher scores of Late-life function and disability scores represent better function (or less disability). A drop in
Short-Form 12 score (physical and mental) represents a reduction in self-reported health status
Multiple comparison analyses performed between Dynapenic Obesity group and other groups: *P < 0.05; #P < 0.001
LLFDI late-life function & disability index, MCS mental component, PCS physical component, SF short form
All values represented are means ± standard deviation or count (%)
ap-values within groups represent significance of change from baseline to follow-up
bp-values represent overall test of difference in means between groups












Table 3 Multivariable regression analysis of primary outcome measures (n = 756)—males
Gait speed 400 m walk LLFDI-Frequency LLFDI-Limitation SF-12 PCS SF-12 MCS
β SE p β SE p β SE p β SE p β SE p β SE p
Intercept 1.77 0.10 <0.001 411.5 12.33 <0.001 53.52 1.73 <0.001 109.4 4.61 <0.001 52.6 3.9 <0.001 54.1 3.49 <0.001
Age −0.008 0.001 <0.001 −0.438 0.147 0.003 −0.103 0.021 <0.001 −0.481 0.056 <0.001 −0.162 0.05 0.001 0.031 0.041 0.46
Dynapenic obesity −0.137 0.023 <0.001 −10.3 2.80 <0.001 1.55 0.419 <0.001 −5.00 1.12 <0.001 −6.12 0.89 <0.001 0.186 0.79 0.81
Dynapenia no obesity −0.048 0.016 0.002 1.57 1.90 0.41 −0.63 0.26 0.15 −3.14 0.69 <0.001 −1.15 0.61 0.06 −0.101 0.54 0.85
Obesity no dynapenia −0.087 0.016 <0.001 −0.97 1.90 0.61 −0.27 0.26 0.29 −4.44 0.69 <0.001 −2.40 0.61 <0.001 −0.931 0.54 0.09
Neither dynapenia nor obesity Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Time −0.01 0.002 <0.001 −0.141 0.430 0.74 – – – – – – −0.44 0.10 <0.001 −0.097 0.09 0.29
x Dyn obes −0.0012 0.004 0.78 −8.07 1.07 <0.001 – – – – – – −0.05 0.24 0.84 0.033 0.22 0.88
X Dyn no obes −0.008 0.003 0.79 −0.775 0.71 0.28 – – – – – – −0.35 0.16 0.03 0.165 0.15 0.27
x Obes no dyn 0.0026 0.003 0.37 −0.79 0.716 0.27 – – – – – – −0.06 0.16 0.70 −0.077 0.15 0.61
x No dyn no obes Ref Ref Ref Ref Ref Ref – – – – – – Ref Ref Ref Ref Ref Ref
All linear mixed models are adjusted for age, physical activity (Physical Activity Scale for the Elderly Score), smoking status, Charlson co-morbidity score, education, race, cohort type (incidence, progression, control).
Referent category is the Neither dynapenia nor obesity group. Time-dependent co-variates are included in time x group interaction. LLDI was only available at 4-year follow-up thereby no time interaction term model
was considered for this measure












Table 4 Multivariable regression analysis of primary outcome measures (n = 1269)—females
Gait speed 400 m walk LLFDI-frequency LLFDI-Limitation SF-12 PCS SF-12 MCS
β SE p β SE p β SE p β SE p β SE p β SE p
Intercept 1.748 0.080 <0.001 454.9 15.5 <0.001 56.3 1.49 <0.001 85.1 3.48 <0.001 51.5 3.47 <0.001 44.2 3.29 <0.001
Age −0.009 0.001 <0.001 −0.90 0.18 <0.001 −0.044 0.168 0.009 −0.267 0.039 <0.001 −0.13 0.04 0.001 0.067 0.04 0.08
Dynapenic obesity −0.141 0.018 <0.001 −6.34 3.61 0.08 −0.685 0.345 0.05 −4.34 0.808 <0.001 −5.15 0.79 <0.001 −0.612 0.75 0.42
Dynapenia no obesity −0.040 0.012 0.001 1.66 2.33 0.48 −0.263 0.22 0.24 −2.38 0.52 <0.001 −1.90 0.52 <0.001 −0.590 0.50 0.24
Obesity no dynapenia −0.082 0.013 <0.001 −4.17 2.43 0.09 −0.743 0.23 0.001 −3.67 0.54 <0.001 −2.42 0.55 <0.001 −0.275 0.52 0.60
Neither dynapenia nor obesity Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Time −0.0083 0.001 <0.001 −1.23 0.46 0.007 — — — — — — −0.38 0.08 <0.001 −0.109 0.077 0.15
x Dyn obes −0.0042 0.004 0.24 −2.25 1.22 0.07 — — — — — — 0.07 0.19 0.71 0.234 0.19 0.22
X Dyn no obes −0.0047 0.0024 0.05 0.063 0.773 0.94 — — — — — — −0.05 0.13 0.70 −0.086 0.13 0.51
x Obes no dyn 0.0005 0.0024 0.85 −1.40 0.78 0.07 — — — – — — −0.32 0.13 0.01 0.126 0.13 0.13
x No dyn no obes ref ref ref Ref Ref ref — — — — — — Ref Ref Ref Ref Ref Ref
All linear mixed models are adjusted for age, physical activity (Physical Activity Scale for the Elderly Score), smoking status, Charlson co-morbidity score, education, race, cohort type (incidence, progression, control).
Referent category is the neither dynapenia nor obesity group. Time-dependent co-variates are included in time x group interaction. LLDI was only available at 4-year follow-up thereby no time interaction term model
was considered for this outcome measure












400 m walk and LLDFI-limitation scores at follow-up
between individuals with obesity without dynapenia,
as compared to dynapenic obese subjects in males
alone. Faster (higher) follow-up gait speed and follow-
up SF-12 PCS scores were observed in females with
obesity without dynapenia as compared to females
with dynapenic obesity.
Tables 3 and 4 demonstrate the sex-specific linear
mixed effects modeling analysis. In both males and fe-
males, there were significant reductions in the dynapenic
obesity group, as compared to those with neither dyna-
penia nor obesity, in gait speed, LLFDI-limitations sub-
scale and SF-12 PCS scores. In males only with
dynapenic obesity, reductions were observed in the
400 m walk test and LLFDI components only. We ob-
served a significant time x dynapenia/obesity interaction
in males for the 400 m walk test but not in any other
measures or in the female sex. This finding highlights
the rate of the decline in this measure alone in males
only. No measures reached statistical significance in any
of the interaction terms in females. Additional file 2a
and b represent adjusted age-stratified functional out-
comes by sex. In both age strata (60–70years, ≥70 years),
both males and females with dynapenic obesity, as
compared to those without dynapenia nor obesity,
had lower gait speeds and SF-12 PCS scores. Subjects
aged ≥70 years had lower gait speeds in both sexes,
but significant differences in LLDFI and 400 m walk
components in males alone. Decline over time (time
x dynapenia/obesity interaction) was observed in both
sexes in the ≥70 year age group. We did not observe
any differences in the MCS score. We detected in-
creased risk of mobility limitations in both males and
females for those with dynapenic obesity at baseline,
as compared to those without dynapenia nor obesity
(Table 5). The relationship was more pronounced in
those aged 70 years and older.
Discussion
Our study provides added longitudinal evidence that
dynapenic obesity, as defined by reduced knee extensor
strength and a BMI ≥ 30 kg/m2, leads to reduced phys-
ical function, higher disability, and lower quality of life
in older adults at risk for and with osteoarthritis of the
knee. Additionally, this subgroup is strongly associated
with increased risk of ADL impairment in both sexes
over time.
Previous cross-sectional studies demonstrate a dispar-
ate interplay between sarcopenia, dynapenia, obesity and
the impact on important geriatric measures in late-life
[14, 16, 17, 32–37]. These results add to the emerging
data that may convince policy makers of the true impact
of this epidemic. For instance, if older adults with dyna-
penic obesity have a 2–3 fold higher risk of ADL limita-
tions, this adversely impacts independence and can lead
to death or institutionalization [38, 39]. Understanding
the natural course of the disease will inform practi-
tioners and researchers as they develop interventions
specifically targeted at the affected population.
Not surprisingly, the majority of our outcomes
dropped from baseline to 48-month follow-up. Gait
speed dropped over time in both sexes but more so in
the dynapenic obesity group. This is consistent with
other studies demonstrating the drop in gait speed and
physical fitness with time in the overall population [30].
What was striking were the changes in SF-12 physical
functioning and LLFDI-limitation subscales in both
sexes, corresponding to the association of quality of life
with physical functioning measures. Yet, our results
show that MCS is not impacted by dynapenic obesity in
this population.
Introducing a time x dynapenia/obesity group inter-
action term in this cross-sectional time series analysis
allowed us to benefit from a number of advantages of
linear mixed-effects regression models including: a) the
Table 5 Odds ratio of incident mobility limitation by category
Dynapenic obesity Dynapenia no obesity Obesity no dynapenia Neither dynapenia nor obesity
Males Unadjusted 3.12 [2.07:4.71] 1.26 [0.87:1.82] 1.92 [1.38:2.68] Ref
Adjusted 2.23 [1.42:3.50] 0.98 [0.66:1.46] 1.98 [1.39:2.80] Ref
Females Unadjusted 4.26 [2.98:6.08] 1.73 [1.26:2.37] 1.83 [1.34:2.48] Ref
Adjusted 2.45 [1.63:3.68] 1.60 [1.15:2.22] 1.47 [1.06:2.04] Ref
60–70 years Unadjusted 3.07 [2.07:4.56] 1.31 [0.89:1.92] 1.95 [1.44:2.62] Ref
Adjusted 1.92 [1.23:3.01] 1.12 [0.74:1.70] 1.65 [1.20:2.27] Ref
70+ years Unadjusted 4.43 [3.05:6.45] 1.49 [1.09:2.05] 1.94 [1.36:2.74] Ref
Adjusted 3.06 [2.01:4.66] 1.36 [0.98:1.88] 1.96 [1.36:2.83] Ref
All models are adjusted for physical activity (Physical Activity Scale for the Elderly Score), smoking status, Charlson co-morbidity score, education, race, cohort type
(incidence, progression, control)
For sex-specific models, age is an additional co-variate; for age-specific models, sex is an additional co-variate
Referent category is the neither dynapenia nor obesity group
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ability to model individual change across time; b) the
ability to incorporate measures without complete data
that is missing at random, making it a superior statistical
measure over a repeated-measures ANOVA (ie: not
requiring complete case ascertainment); and c) the cap-
acity to incorporate variables at different time periods.
While differences were observed between categories, we
were surprised that despite a considerable number of
primary outcomes, including gait speed, 400 m walk,
and SF-12, only the 400 m walk distance significantly de-
clined in those with dynapenic obesity. These suggest
three possible phenomena. First, the divergent scores in
each measure likely occurred before 60 years of age
since these differences were present at baseline. Sec-
ond, the rate of change for the 400 m walk test dif-
fered significantly in those with dynapenia in those
aged ≥70 years implying that a decline is observed
later in life as well. Third, this cohort excluded those
with TKA, death, low BMI and were community-
dwelling adults participating in a research study. A
number of subjects were excluded who had consider-
able co-morbidity, lower socioeconomic status, and
pain. A comparison analysis of missing vs. included
subjects was performed and confirmed that our co-
hort may have been healthier and thus we may not
have observed the magnitude of the expected trends.
The trajectories parallel other population groups, in-
cluding one with a normal BMI with central adipos-
ity, where the magnitudes of such declines occurred
earlier in life [40]. Observing these differences in lar-
ger and older populations can better define some of
these trajectories.
The Foundation for the National Institutes for Health
Sarcopenia consensus suggest the use of two measures
to account for sarcopenia: appendicular skeletal mass
and grip strength [5]. The former can only be measured
using sophisticated research tools and clinically is im-
practical; the latter can easily be incorporated into a
busy primary care practice using a dynamometer as a
component of sarcopenia. A number of studies have
demonstrated the relationship between knee extensor
strength [16, 41–43] and grip strength [44, 45] on ad-
verse outcomes in older adults. Knee extensor strength
is often available in research centers and training facil-
ities, and has been proven in one study to be superior to
that of grip strength in assessing strength in assisted liv-
ing populations [46]. Future study in this population
should examine grip strength, in lieu of knee extensor
strength, as a marker for dynapenia.
Classification bias is an overarching concern in a num-
ber of studies examining prevalence and outcomes of
dynapenic obesity [47]. Our study is no exception. First,
we used knee extensor strength and classified low
strength as subjects in the lowest sex-specific tertile.
While other authors have used similar approaches [16],
ideally, national, population-specific norms of low knee
extensor strength are needed and should be used. Sec-
ondly, we fully acknowledge that we used BMI as a
measure of obesity and that this anthropometric meas-
ure, while easy to use clinically, may suboptimally assess
fat in older adults [48]. We considered using waist cir-
cumference, however, the majority of participants
(>75 %) had an elevated waist circumference based on
criteria. Third, ideally a comparison of dynapenic obesity
defined using either low grip strength or low appendicu-
lar skeletal muscle mass adjusted by BMI as proposed by
Studenski should be considered in future study designs
[5]. Fourth, normalization of knee extensor strength by
muscle mass could account for differences in strength
based on body size. Without full body composition data,
this approach would not allow us to best understand the
impact of dynapenic obesity on our outcome measures.
Lastly, changes in body composition with aging are
known to impact future risk of future function and dis-
ability which could not be accounted in this particular
analysis.
The dataset was initially meant to observe the differ-
ences between three distinct subgroups on risk factors
and progression of osteoarthritis. By stratifying our re-
sults into four categories by sex, we lost considerable
statistical power in our modeling to be able to compare
the effect of dynapenic obesity on the three subgroups.
Inherently, the information obtained from such a study
would be very important and critical in the understand-
ing of the natural history, progression and possible
mechanisms to incident disability and their trajectory
observed in clinical practice. Future studies with ad-
equate sample size can identify the absolute changes and
rates of declines in those with and without knee OA.
We recognize that this study has a number of other
limitations. Clinical studies risk participants dropping
out, and often dropouts have higher degrees of co-
morbidity and lower socioeconomic status potentially
biasing our results. A 4-year time period may not be suf-
ficient to observe the impact of these results in a rela-
tively ‘young’ population with minimal co-morbidity as
reflected by the Charlson co-morbidity index. In fact,
our age-stratified analysis suggested that age indeed is a
factor on these important geriatric outcomes. Other pa-
rameters that clearly influence quality of life and objective
measurable outcomes, including the degree of depression,
involvement of hip osteoarthritis, and muscle circumfer-
ence could be incorporated in future analysis with in-
creased study power. While these could be incorporated
in the current study, we would run the risk of over-
adjustment. Lastly, we relied on self-reported and non-
standardized functional assessments (ADLs) which may
impact our estimates. Future study should consider
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identifying biomarkers associated with both dynapenia
and obesity that could possibly explain the mechanisms
involved in this trajectory.
Conclusion
Dynapenia with obesity is associated with adverse object-
ive and self-reported functional outcomes and reduced
physical functioning and self-reported health. Encour-
aging such patients to engage in tailored interventions
consisting of caloric restriction, regular resistance train-
ing, and targeted nutritional supplementation, should be
considered to improve overall performance and reduce
the risk of disability.
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